A phase II trial shows that a chemotherapy-free regimen of dasatinib and blinatumomab produces molecular responses in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. The study found that 60% of patients had molecular responses after two cycles of blinatumomab and 71% had molecular responses after five cycles.

You do not currently have access to this content.